Why Europe’s CDMO Sector Must Learn to Dance with Disruption
-
by Joe Renny
January 14, 2026
-
5 min
The European CDMO sector stands at a pivotal moment defined by disruption from inflation, geopolitical changes, and health crises. These challenges present opportunities for growth through antifragility, a concept advocating that organizations can thrive on adversity. By stepping beyond the subcontractor role, CDMOs can secure their importance in the biopharma ecosystem. They must exploit their strengths in high-value production and regulatory credibility to thrive amidst disruptions like Brexit and the Biosecure Act, framing these challenges as pathways to a resilient future.
1. Antifragility allows organizations to thrive on adversity. 2. CDMOs can redefine their roles in biopharma. 3. The Biosecure Act affects pharmaceutical trade. 4. Emphasis on modular and digital production is vital. 5. ESG compliance offers competitive advantages in Europe. 6. Disruption should be seen as a growth opportunity for CDMOs. 7. Europe is not declining; it is evolving industrially. 8. Crisis can turn into opportunity when strategically navigated.
Listen Tab content
